This week on “The Top Line,” we explore the impact of environmental, social and governance measures, commonly known as ESG, on the pharmaceutical industry.
Fraiser Kansteiner of Fierce Pharma engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights. Greffet makes a compelling business case for integrating ESG into the core of drugmakers' DNA. He also discusses Eli Lilly’s specific ESG initiatives, illustrating how these strategies connect to the company’s extensive history.
To learn more about the topics in this episode:
- Patient groups want pharma to improve on ESG—and are pushing for a seat at the table
- Setting sights on suppliers: How biopharma is tackling the environment in its ESG commitments
- Seeing green, AstraZeneca lays down £100M for 15-year renewable gas project in UK
- Gilead receives awards, pledges commitment to COVID, the environment and inclusion in 2023